Neidhardt M, Bailey C C, Gnekow A, Kleihues P, Michaelis J, Wellek S
Klin Padiatr. 1987 May-Jun;199(3):188-92. doi: 10.1055/s-2008-1026787.
In both trials the principle of "sandwich" chemotherapy (administered between surgery and postoperative irradiation) is studied in medulloblastoma. GPO-MBL 80 was essentially a one-arm trial; results after a mean observation period of 3 years show an expected event-free survival rate of 46% at 6 years. "Maintenance" chemotherapy with CCNU and vincristine did not further improve the results. Preliminary results of the joint, prospective, randomised forearm SIOP-GPO trial MED 84 are presented. It is apparently too early to answer any of the two main questions asked by this trial: a) is "sandwich" chemotherapy (as administered) of any value? b) can radiotherapy doses to the supratentorial area and to the spine be moderately reduced in so-called "low risk" patients without compromising long-term results? Thus far, we cannot observe any prognostic influence of the "classical" risk factors as established by other studies.
在两项试验中，研究了“三明治”化疗（在手术和术后放疗之间进行）治疗髓母细胞瘤的原则。GPO-MBL 80本质上是一项单臂试验；平均观察期3年后的结果显示，6年时预期的无事件生存率为46%。用环己亚硝脲和长春新碱进行的“维持”化疗并未进一步改善结果。本文介绍了联合、前瞻性、随机前臂SIOP-GPO试验MED 84的初步结果。要回答该试验提出的两个主要问题中的任何一个，显然都为时过早：a）（所采用的）“三明治”化疗是否有价值？b）在所谓的“低风险”患者中，能否适度降低幕上区域和脊柱的放疗剂量而不影响长期效果？到目前为止，我们未观察到其他研究所确定的“经典”风险因素有任何预后影响。
